Liver Transplantation
Conditions
Brief summary
In this study, the investigators aim to analyse the effect of Omega 3 fatty acid supplementation on recipients undergoing living donor liver transplantation. In Group A, the patients receive Omega 3 fatty acid on preoperative day 1, intraoperatively and up to day 5 post operatively; and the effect of omega 3 fatty acid supplementation on early allograft dysfunction, its correlation with occurrence of postoperative complications and liver regeneration measured by CT volumetry on Day 7. Group B, the patients are controls for the study and hence attempt to find out the effect of omega 3 fatty acid supplementation on outcome of recipients of Living donor liver transplantation. the investigators will analyse the data and elucidate the value of omega 3 fatty acid supplementation in reducing the occurrence of early allograft dysfunction , complications and effect on liver regeneration in recipients of Living donor liver transplantation.
Interventions
DRUGOmega 3 fatty acid
10% Omega-3 fatty acid oil will be supplemented in intravenous form from preoperative day 1, intra-operatively (anytime during surgery before reperfusion of graft) and from post operative day 1 to day 5 in the study group. The preparation used will be 100 ml injection which contains 10 gm of Omega 3 fatty acids.
Sponsors
Institute of Liver and Biliary Sciences, India
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
* All elective liver transplant recipients * Adult patients * Those who consent
Exclusion criteria
* Liver transplantation for fulminant hepatic failure * Re-transplantation * Known allergy to the study emulsion
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Early Allograft Dysfunction | Post operative day 7 | To study the correlation with early allograft dysfunction using definition of early allograft dysfunction based on laboratory parameters (presence of one or more of the following : bilirubin \>or=10mg/dL on day 7, international normalized ratio \>or=1.6 on day 7, and alanine or aspartate aminotransferases \>2000 IU/L within the first 7 days) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Liver function test - trend | Till period of hospital stay, average of 1 month | To study the correlation between supplementation of omega-3 fatty acids and trend in post-operative LFTs |
| Complications | Till period of hospital stay, average of 1 month | Post-operative complications |
| ICU and hospital stay | Till period of hospital stay, average of 1 month | To determine the total hospital stay and ICU stay |
Countries
India
Contacts
Primary ContactSenior Resident
Outcome results
None listed